Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors  by Harnett, John D. et al.
Kidney International, Vol. 47 (1995), pp. 884—890
Congestive heart failure in dialysis patients: Prevalence,
incidence, prognosis and risk factors
JOHN D. HARNETT, ROBERT N. FOLEY, GLORIA M. KENT, PAUL E. BARRE, DAVID MURRAY,
and PATRICK S. PARFREY
Division of Nephrology and Clinical Epidemiology, Memorial University of Newfoundland and the Division of Nephrology, McGill University,
Montreal, Canada
Congestive heart failure in dialysis patients: Prevalence, incidence,
prognosis and risk factors. Cardiovascular disease is the most common
cause of death in dialysis subjects. Congestive heart failure (CHF) is a
common presenting symptom of cardiovascular disease in the dialysis
population. Information regarding prevalence, incidence, risk factors and
prognosis is crucial for planning rational interventional studies. A pro-
spective multicenter cohort study of 432 dialysis patients followed for a
mean of 41 months was carried out. Prospective information on a variety
of risk factors was collected. Annual echocardiography and clinical
assessment was performed. Major endpoints included death and the
development of morbid cardiovascular events. One hundred and thirty-
three (3 1%) subjects had CHF at the time of initiation of dialysis therapy.
Multivariate analysis showed that the following risk factors were signifi-
cantly and independently associated with CHF at baseline: systolic dys-
function, older age, diabetes mellitus and ischernic heart disease. Seventy-
six of 299 subjects (25%) who did not have baseline CHF subsequently
developed CHF during their course on dialysis. Compared to those
subjects who never developed CHF (N = 218) multivariate analysis
identified the following risk factors for the development of CHF: older
age, anemia during dialysis therapy, hypoalbuminernia, hypertension
during dialysis therapy, and systolic dysfunction. Seventy-five of the 133(56%) subjects with CHF at baseline had recurrent CHF during follow-up.
Independent and significant risk factors for CHF recurrence were isch-
ernie heart disease and systolic dysfunction, anemia during dialysis therapy
and hypoalburninemia. The median survival of subjects with CHF at
baseline was 36 months compared to 62 months in subjects without CHF.
In this study the prevalence of CHF on starting ESRD therapy and the
subsequent annual incidence was high. CHF was a strong, independent,
adverse prognostic indicator. Risk factors for CHF include older age,
pre-existing cardiac diseases (systolic dysfunction and ischemic heart
disease), and potentially reversible abnormalities related to chronic ure-
mia (anemia, hypertension and hypoalbuminemia).
Cardiac disease is the most common cause of death in dialysis
patients, accounting for about 40% of deaths in this group [1, 2].
Congestive heart failure is a frequent clinical manifestation, and is
associated with systolic failure, left ventricular hypertrophy and
ischemic heart disease [3]. Congestive heart failure, present on the
initiation of end-stage renal disease therapy, is an adverse,
independent, prognostic indicator of mortality [4]. Recurrent
congestive heart failure in patients established on dialysis has an
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adverse prognosis [5]. However, little prospective data exists
concerning the risk factors for congestive heart failure, and the
role of underlying cardiac disease in the etiology of congestive
heart failure in dialysis patients. The best research design to
identify potentially reversible risk factors, whose treatment could
be tested in clinical trials, is a prospective study of a cohort of
dialysis patients without congestive heart failure at baseline, some
of whom subsequently develop congestive heart failure.
Therefore a prospective study of a cohort of 432 consecutive
patients, who survived at least six months from the start of dialysis,
was undertaken. To determine risk factors for congestive heart
failure, patients with congestive heart failure on initiation of
end-stage renal disease therapy were compared to those without,
and patients who did not have congestive heart failure at baseline,
but subsequently developed it, were compared to those who never
developed heart failure. We hypothesized that patients with
congestive heart failure at baseline and who had a recurrence
during their life on dialysis have different risk factors from those
who never had a recurrence. These two groups were also corn-
pared.
Methods
This prospective cohort study was carried out in three centers,
the Royal Victoria Hospital in Montreal, Quebec starting in 1982,
the General Hospital, St. John's starting in 1984 and the Grace
Hospital, St. John's starting in 1985. Recruitment finished in June
of 1991. Eligibility criteria for the study included survival for six
months or more on dialysis, because we intended to use the data
to design clinical trials of interventions in the treatment or
prevention of cardiac disease in chronic uremia. Another criterion
was the availability of a technically adequate echo within one year
of initiating renal replacement therapy.
At the time of initiation of dialysis and at annual intervals
thereafter, clinical assessment was performed to detect risk fac-
tors for the presence of cardiovascular disease. Baseline and
annual echocardiography was performed using M-mode and two
dimensional ultrasonography according to the criteria set forth by
the American Society of Echocardiographers. Left ventricular
mass index was calculated using either the regression corrected
American Society of Echocardiography cubic formula or the
formula of Devereux and Reichek, depending on whether the
endocardium was included in the estimation of ventricular wall
thickness. Both of these methods are highly correlated and have
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strong validity when compared to autopsy data [6]. Echocardiog-
raphy was performed when the patient was considered to be at or
close to "dry weight." This assessment was based on clinical
parameters. In addition to echocardiography 55% of patients also
had radionuclide scans of the left ventricle to calculate ejection
fraction. This was not however an entry requirement for the study,
as it was not performed in one hospital. At monthly intervals the
following data were collected: predialysis blood pressure, inter-
dialytic weight gain, predialysis hemoglobin, serum urea, serum
creatinine, electrolytes, bicarbonate, calcium, phosphorus, albu-
min and alkaline phosphatase. In addition to the annual clinical
assessment and echocardiography the following were also under-
taken: review of hospital admissions, measurement of serum
cholesterol, parathyroid hormone levels, serum aluminum and
ferritin levels. In addition, chest x-ray, EKG and metabolic bone
surveys were also performed. Any changes in renal replacement
therapy were noted. The presence and type of vascular access was
noted as was the occurrence of blood transfusions, admissions to
hospital, death notes and autopsy results. This study was initiated
before measurement of dialysis adequacy (Kt/V) was routine.
Data on dialysis prescription and dialyzer use were not studied.
Definitions
Congestive heart failure. Dyspnea plus two of the following:
raised jugular venous pressure, bibasilar crackles, pulmonary
venous hypertension or interstitial edema on chest x-ray [3].
Ischemic heart disease. Present or previous history of angina,
myocardial infarction, coronary artery bypass surgery or percuta-
neous transluminal angioplasty.
Peripheral vascular disease. Symptoms of, or surgery for periph-
eral vascular disease.
Dysrhythmia. Atrial or ventricular rhythm disorder requiring
therapy.
LV hypertrophy. Mass index >100 g/m2 in females and mass
index >131 g/m2 in males. These values are the upper limits of
normality among healthy participants in the Framingham Heart
Study [71.
Systolic dysfunction. Left ventricular ejection fraction 40% on
radionuclide scan or fractional shortening 25% on echocardio-
gram.
Analysis
The following outcome measures were used for this analysis:
death, the recurrence of CHF and the occurrence of de novo CHF.
Patients were censored at the time of renal transplantation or at
the final follow-up.
Normally distributed continuous variables were compared using
t-tests. Categorical variables were compared using Chi squared
tests. Stepwise logistic regression analysis was used to identify
which baseline variables were associated with the occurrence of
congestive heart failure at the start of dialysis. Variables were
entered using a forward stepping procedures in which the order
was determined using estimates of asymptotic variance, with F>
0.10 to enter and P < 0.15 to remove at any step. Univariate
survival analysis was carried out using life table analysis by the
product limit method. All statistical tests are two-sided with a P
value of < 0.05 taken to indicate statistical significance. The
independent power of different variables to predict new CHF and
mortality was assessed using Cox's Proportional Hazards Model.
All statistical analysis was carried out using BMDP software [8].
Five hundred and eighteen patients were identified who had
survived at least six months from the start of endstage renal
disease therapy and 432 of these 518 (84%) had an adequate
echocardiogram within one year of starting dialysis therapy.
Ecliocardiography was performed at a mean (standard deviation)
interval of 3.3 (3.9) months from the time of first dialysis. Mean
duration of follow-up was 41.1 (25.7) months. Hemodialysis,
peritoneal dialysis and renal transplantation accounted on aver-
age for 18.8, 12.8 and 9.5 months, respectively, of total follow-up.
The mean age of the patients was 51 years. Sixty-four percent of
the patients were males and 27% were diaetics. The vast majority
of patients were Caucasian. An initial report on the adverse
impact of clinical and echocardiographic variables on patient
survival has been recently published [9].
Results
Figure 1 demonstrates that, on initiation of ESRD therapy,
31% of patients had congestive heart failure or a history of this
condition, 56% of whom had a recurrence of heart failure during
dialysis therapy. Twenty-five percent of patients without heart
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Fig. 1. The prevalence and incidence of
No Incomplete congestive heart failure in a cohort of 432 dialysis
patients who survived at least 6 months from the
218 Data 5 start of ESRD therapy.
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Table 1. Demographic and clinical data on starting ESRD therapy in
those with and without congestive heart failure on the initiation of
dialysis therapy
C
(N =
N
HF
133)
%
NoCHF
(N = 299)
N % P
Male 80 60 198 66 NS
Cigarette smoking 53 40 98 33 NS
Diabetes mellitus 56 42 60 20 <0.0001
Myocardial infarction 34 26 18 6 <0.0001
Angina 46 35 37 10 <0.0001
Coronary artery 8 6 6 2 0.03
bypass graft
Peripheral vascular 23 17 13 4 <0.0001
disease
Arrhythmias 20 15 11 4 <0.0001
Mean SD Mean sn
Age years 59 14 48 17 <0.0001
Serum cholesterol 5.4 1.8 5.2 1.5 NS
mmol/liter
Serum creatinine 801 348 930 426 0.001
pmol/liter
Systolic BP mm Hg 152 26 151 24 NS
Diastolic BP mm Hg 82 15 84 13 NS
Serum albumin glliter 34 5.5 35 6 NS
Hemoglobin_g/liter 85 18 83 16 NS
failure at baseline developed de novo heart failure during dialysis
therapy.
Congestive heart failure on initiation of ESRD therapy
Table 1 demonstrates that patients with congestive heart failure
at baseline were significantly older, with a higher prevalence of
diabetes mellitus, ischemic heart disease, and lower baseline
serum creatinine values. There were no differences in serum
cholesterol or albumin, systolic and diastolic blood pressure, or
hemoglobin levels on initiation of ESRD therapy. Table 2 pre-
sents data on echocardiographic characteristics at baseline. Sub-
jects with CHF had significantly higher left ventricular mass index,
increased left ventricular end diastolic and end systolic diameters,
and lower fractional shortening, when compared to those without
congestive heart failure at baseline. There was also a higher
prevalence of systolic dysfunction, and left ventricular dyskinesia
(which included global and segmental dyskinesia). Multiple logis-
tic regression (Table 3) indicates that systolic dysfunction, older
age, diabetes mellitus and ischemic heart disease were indepen-
dently associated with the occurrence of congestive heart failure
at baseline, whereas LV mass index (LVMI) was not.
The median survival of subjects with congestive heart failure
was 36 months, compared to 62 months in subjects without
congestive heart failure (P < 0.0001) (Fig. 2). This adverse
prognosis was independent of age, diabetes, ischemic heart dis-
ease, hemoglobin level during dialysis therapy, serum albumin,
diastolic blood pressure during dialysis therapy, and LVMI (Table
4). There was no difference in survival among patients with CHF
comparing those with and without systolic dysfunction controlling
for age and diabetes.
Table 2. Echocardiographic data on starting ESRD therapy in those
with and without congestive heart failure on the initiation of dialysis
therapy
CHF
(N = 133)Mean SD
No CHF
(N = 299)
Mean SD P
LV mass index g/m2 172 47 152 48 <0.000 1
LV end diastolic 53 8 51 7 0.009
diameter mm
LV end systolic 37 9 33 7 <0.0001
diameter mm
Post LV wall thickness 12 2 12 2.5 NS
in diastole mm
Fractional shortening 30.5 9 35.4 7 <0.0001
%
N % N %
Systolic dysfunction 44 33 20 <0.0001
LV dyskinesia 47 36 33 11 <0.0001
Normal 15 11 78 26 0.0009
echocardiogram
Table 3. Multiple logistic regression showing factors independently
associated with congestive heart failure present at the initiation of
dialysis therapy
Odds ratio P
Age (per 10 years) 1.44 <0.001
Diabetes mellitus 2.64 <0.001
Ischemic heart disease 1.98 0.021
Systolic dysfunction 5.34 <0.001
LV mass index NA NA
Hemoglobin at start NA NA
Serum albumin at start NA NA
Diastolic blood pressure NA NA
at start
NA is not associated.
De novo development of congestive heart failure during
dialysis therapy
These analyses studied 299 patients who were free of congestive
heart failure at the start of dialysis. Seventy-six of these developed
CHF after a median time of 15 months, 218 did not develop CHF
up to the time of last follow-up or censoring, and in 5 patients we
had incomplete data. Subjects who developed de novo congestive
heart failure during the course of dialysis were significantly older,
with a higher prevalence of myocardial infarction at baseline,
lower mean of serial serum albumin levels, and lower mean
hemoglobin levels during follow-up, compared to patients who
never developed heart failure (Table 5). The overall prevalence of
cardiovascular disease in those who developed de novo CHF was
much lower than in the group who had congestive heart failure at
baseline (Tables 1 and 5). Subjects who developed de novo
congestive heart failure had increased left ventricular mass index,
elevated left ventricular end diastolic diameter, and a higher
prevalence of systolic dysfunction at baseline, when compared to
those patients who remained free of congestive heart failure
(Table 6). Multivariate analysis, using Cox's Proportional Hazards
Model, identified the following independent risk factors for the
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Fig. 2. Unadjusted survival curves comparing
those with congestive heart failure on initiation of
ESRD therapy to those without. P < 0.001.
Table 4. The effect of clinical and echocardiographic variables on
starting ESRD therapy, and of mean hemoglobin, albumin and diastolic
blood pressure levels measured during dialysis therapy, on survival
using Cox's Proportional Hazards Model
Odds ratio P
Age (per 10 years) 1.25 0.0036
Diabetes mellitus 1.99 0.0003
Ischemic heart disease 1.38 0.1087
Congestive heart failure 1.89 0.0013
Systolic dysfunction 1.53 0.059
Hemoglobin per 10 g fall 1.14 0.048
Serum albumin per 5 g fall 1.61 <0.0001
Diastolic blood pressure 1.13 0.0267
per 5 mm fall
LVMI per 20 g/m2 1.04 0.352
development of congestive heart failure: older age, anemia,
hypoalbuminemia, high diastolic blood pressure, and perhaps
systolic dysfunction (Table 7). The median survival following the
development of new congestive heart failure during the course of
dialysis was 18 months.
In the subset of hemodialysis patients who developed de novo
CHF there was no difference in weight gains between dialyses,
compared to those who never developed CHF (2.14 1.16 kg vs.
2.05 0.91 kg, P = NS). There was no difference in the
proportions who had average inter-dialytic weight gains > 4 kg
(0% vs. 2.7%).
Recurrent heart failure
Of the 133 patients who had congestive heart failure at baseline,
75 developed recurrent heart failure and 58 remained free of
congestive heart failure recurrence during the time of follow-up.
The median survival for those with recurrent heart failure was 29
Table 5. Demographic and clinical data on starting ESRD therapy,
together with serial blood pressure and laboratory values, in those who
developed de novo congestive heart failure following the initiation of
dialysis therapy, compared to those who did not develop heart failure
New onset
CHF No CHF
(N 76) (N = 218)
N % N % P
Male 46 61 149 68 NS
Cigarette smoking 28 37 68 31 NS
Diabetes mellitus 18 26 38 17 NS
Myocardial infarction 8 10.5 10 4.6 <0.0001
Angina 10 13 20 9 NS
Coronary artery 2 2.6 4 1.8 NS
bypass graft
Peripheral vascular 3 4 10 5 NS
disease
Arrhythmia 5 7 6 3 NS
rHuEPO therapy 28 37
Mean SD
50 23
Mean SD
0.02
P
Age years 54 16 46 17 <0.0001
Mean serum 5.1 1.5 5.25 1.5 NS
cholesterol
mmol/liter
Mean serum 961 239 965 303 NS
creatinine pmol/liter
Mean systolic BP 150 25 151 24 NS
mm Hg
Mean diastolic BP 83 13 84 14 NS
mm Hg
Mean serum albumin 35 6 37 4 0.02
giliter
Mean hemoglobin 83 17 88 16 0.05
glliter
Serial values were obtained from the start of dialysis to development of
de novo congestive heart failure or to last follow-up on dialysis.
No CHF
0 6 12 18 24 30 36 42 48 54 60 66
Time, months
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Table 6. Echocardiographic data on starting ESRD therapy in those
who subsequently developed de nova congestive heart failure compared
to those who did not
New onset
CHF NoCHF
(N = 76)Mean SD
(N = 218)
Mean SD P
LV mass index g/m2
LV end diastolic
164 4053 7 148 5050 6 0.0070.03
diameter mm
LV end systolic
diameter mm
34 8 32 6 0.16
Posterior LV wall 12 1.5 12 2.8 NS
thickness in
diastole mm
Fractional shortening
%
36 9 35 6 NS
N % N % P
Systolic dysfunction 10 13 9 4 0.006
LV dyskinesia 10 13 18 8.4 NS
Table 7. Independent risk factors for the development of de nova
congestive heart failure in dialysis subjects
Risk factor Relative risk P
Age decade 1.32 0.0045
Diabetes mellitus 1.63 0.0969
Ischemic heart disease 1.00 0.9949
Systolic dysfunction 2.05 0.0814
Hemoglobin per 10 g fall 1.49 <0.0001
Serum albumin per 5 g fall 1.34 0.0073
Diastolic blood pressure 1.32 0.0005
per 5 mm increase
LV mass index per 20 gIm2 1.04 0.494
The data are a multivariate analysis using Cox's Proportional Hazards
Model, of the impact of clinical and demographic factors present at the
initiation of ESRD therapy, and of mean serial hemoglobin, albumin, and
blood pressure levels measured during dialysis therapy.
months and for those without it was 45 months (P = 0.006). Table
8 reveals that patients with recurrent heart failure were signifi-
cantly older, with a higher prevalence of ischemic heart disease.
Table 9 shows no significant differences in echocardiographic
measurements. However multivariate analysis, using the Cox's
Proportional Hazards Model, shows that the risk factors for
recurrent congestive heart failure are the presence of ischemic
heart disease at baseline, anemia and hypoalbuminemia during
dialysis therapy and the presence of baseline systolic dysfunction
on echocardiogram (Table 10).
Discussion
The prevalence of congestive heart failure on the initiation of
end-stage renal disease was high (31% of patients in a selected
population of those who survived at least 6 months) as was its
incidence after the initiation of dialysis: 25% of patients without
heart failure at baseline subsequently developed heart failure, at
a rate of 7% per year. These rates are similar to those observed in
the Canadian hemodialysis morbidity study [10]. The prognosis of
congestive heart failure was poor; in those with heart failure at
baseline the median survival was 36 months. This adverse prog-
Table 8. Demographic and clinical factors present at the initiation of
ESRD therapy, together with serial blood pressure and laboratory data
in those who had congestive heart failure on initiation of ESRD
therapy, who did and who did not develop a recurrence of congestive
heart failure, during their life on dialysis
Recurrent No
CHF recurrence
(N=75) (N=58)
N % N % P
Male 41 55 39 67 NS
Cigarette smoking 32 43 21 37 NS
Diabetes mellitus 30 45 26 40 NS
Myocardial infarct 27 36 7 12 0.001
Angina 33 44 13 22 0.009
Coronary artery 3 4 5 9 NS
bypass graft
Peripheral vascular 16 21 7 12 NS
disease
Arrhythmia 12 16 8 14 NS
rHuEPO therapy 19 26 17 30 NS
Mean so Mean SD
Age 61 12 55 16 0.02
Serum cholesterol 5.4 1.8 5.3 1.6 NS
mmol/liter
Serum creatinine 796 359 808 337 NS
pinol/liter
Systolic BP mm Hg 150 24 154 23 NS
Diastolic BP 82 16 82 13 NS
mm Hg
Serum albumin 33 5.7 34 5.3 NS
g/liter
Hemoglobin g/liter 83 20 87 17 NS
Serial values were obtained from the initiation of ESRD therapy to the
development of first recurrence of heart failure or to last follow-up on
dialysis.
Table 9. Echocardiographic data on starting ESRD therapy in patients
who had congestive heart failure on initiation of ESRD therapy,
comparing those who had and who did not have a recurrence of CHF
No
Recurrent recurrence
CHF of CHF
(N=75) (N=58)
Mean SD Mean so P
LV mass index g/m2 159 37 161 36 NS
LV end diastolic 53 8 53 8 NS
diameter mm
LV end systolic 38 9 36.5 9 NS
diameter mm
Posterior LV wall 12 1.8 12 2.4 NS
thickness in diastole
mm
Fractional shortening % 30 9
N %
31.5 9
N %
NS
P
Systolic dysfunction 30 40 14 25 0.06
LV dyskinesia 31 42 16 28 NS
Normal echocardiogram Il 15 9 15 NS
nosis was independent of age, diabetes and ischemic heart disease,
confirming a long recognized observation [4]. Patients who never
had a recurrence of congestive heart failure had a better prognosis
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Table 10. Independent risk factors for congestive heart failure
recurrence
Risk factors Relative risk P
Age (per 10 years) 1.09 0.4532
Diabetes mellitus 1.34 0.315
Ischemic heart disease 3.10 0.0019
Systolic dysfunction 1.92 0.0170
Hemoglobin per 10 g fall 1.25 0.020
Serum albumin per 5 g fall 1.37 0.048
Diastolic blood pressure 1.02 0.318
per 5 mm increase
LV index per 20 g/m2 1.00 0.994
Multivariate analysis using Cox's Proportional Hazards Model was used,
of demographic and clinical factors present on starting ESRD therapy and
of mean hemoglobin, albumin and blood pressure levels measured during
dialysis therapy.
(median survival 45 months) than those who had a recurrence
(29 months), but this survival was lower than those without
congestive heart failure at baseline (62 months).
In this prospective study independent predictors for the pres-
ence of congestive heart failure on initiation of end-stage renal
therapy were systolic dysfunction, older age, diabetes mellitus,
and ischemic heart disease. Independent predictors for the recur-
rence of heart failure following the initiation of dialysis therapy
were ischemic heart disease, anemia, hypoalbuminemia, and
systolic dysfunction at baseline. However the best design to
identify risk factors for the development of new congestive heart
failure is the nested case control study, in which patients without
congestive heart failure at baseline are followed prospectively.
Patients who develop congestive heart failure de novo while on
dialysis can then be compared to those who do not. The indepen-
dent risk factors identified in this group were older age, low mean
of serial hemoglobin levels, hypoalbuminemia, diastolic hyperten-
sion, and perhaps systolic dysfunction at baseline. Thus it appears
that the most important underlying cardiac diseases predisposing
to congestive heart failure include systolic dysfunction and isch-
emic heart disease, and the most important uremia related risk
factors, independent of underlying cardiac disease and present
during dialysis therapy, include anemia, hypoalbuminemia and
hypertension. This study does not rule out excess salt and water
retention as a cause of CHF, but we found no evidence that
chronic excessive weight gains between dialyses predisposed to the
development of CHF. Furthermore when mean inter-dialytic
weight gain was included in the multivariate models it did not
predict CHF.
We have already reported that anemia is an independent
predictor of mortality in chronic uremia [11]. The current analysis
suggests that anemia predisposes to cardiac morbidity. Conse-
quently, amelioration of anemia with erythropoietin may improve
both cardiac morbidity and mortality. Several reports [12, 13] have
identified hypoalbuminemia as an adverse prognostic factor. This
study is the first to suggest that its adverse effect may be exerted
through the heart, as it is associated with both the recurrence of
congestive heart failure and with the de novo development of
heart failure during end-stage renal disease therapy. The mecha-
nisms whereby hypoalbuminemia leads to cardiac dysfunction is
unclear. Hypertension is an accepted risk factor for congestive
heart failure in the general population [14]. In our patients with
chronic uremia blood pressure control has been reasonable during
dialysis therapy: mean blood pressure was 143 17/80 10 mm
Hg, but high mean diastolic values are associated with the
development of congestive heart failure. We have previously
shown that a low diastolic blood pressure independently predicts
overall mortality in dialysis subjects.
Much research remains to be undertaken. Cohort studies of
subjects with chronic uremia (before and after initiation of
dialysis) to identify the most important potentially reversible risk
factors for systolic dysfunction, LV hypertrophy and ischemic
heart disease should be carried out. Intervention studies to test
the effect of normalization of hemoglobin using erythropoietin
and to identify the best target hemoglobin are needed. Correction
of hypoalbuminemia by nutritional intervention or by increased
amount of dialysis, and trials of antihypertensive agents to identify
the optimal target blood pressure in these subjects are also
necessary. This study did not investigate the effect of dialysis
prescription on the natural history of congestive heart failure, an
important area for future endeavors.
We conclude that the prevalence and incidence of congestive
heart failure is high, that its prognosis is adverse, that predispos-
ing cardiac diseases include systolic dysfunction and ischemic
heart disease, and that potentially reversible risk factors present
during dialysis therapy include anemia, hypoalbuminemia and
hypertension.
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